Pharos iBio Co., Ltd.
KKRX:3888705,960.00
KRW
+40.00
(+0.68%)
ISIN
KR7388870008
Return %
Stock
S&P 500
1Y
12.45
13.14
3Y
-42.14
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jung-Hyuk Yoon
- Full Time Employees
- 33
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Anyang-si South Korea
- IPO Date
- Jul 27, 2023
- Website
- pharosibio.com
- Similar Companies
- Business
- Pharos iBio Co., Ltd. is a South Korea-based biotechnology and clinical-stage biopharmaceutical company that specializes in the discovery and development of novel small-molecule therapeutics for rare and refractory diseases utilizing artificial intelligence and big data technologies. The company operates through two core business activities: Drug Discovery and Development, and AI Platform Services. Pharos iBio develops targeted therapeutics leveraging its proprietary AI-driven drug discovery platform, Chemiverse, which utilizes deep learning algorithms, protein structure modeling, and molecular interaction databases containing hundreds of millions of compound structures to accelerate target identification, lead generation, and candidate optimization across oncology and intractable illness indications. The company's primary research and clinical pipeline includes: PHI-101 (lasmotinib), a selective oral FLT3 kinase inhibitor under clinical evaluation for relapsed or refractory acute myeloid leukemia, recurrent platinum-resistant ovarian cancer, and triple-negative breast cancer; PHI-501, a pan-RAF and DDR dual inhibitor developed for refractory solid tumors, malignant melanoma, and colorectal cancer, designed for monotherapy and synergistic combination regimens with immune checkpoint inhibitors; PHI-701, a next-generation fourth-generation EGFR tyrosine kinase inhibitor targeting C797S resistance mutations in non-small cell lung cancer; PHI-301, a targeted small-molecule candidate for refractory lung cancer; and PHI-601, an investigational menin inhibitor targeting acute leukemias. In addition to pipeline development, the company provides collaborative AI-based drug discovery, molecular modeling, and preclinical research validation services to external biopharmaceutical enterprises, academic medical centers, and research institutions through its Chemiverse module suite. In recent developments, Pharos iBio completed its global Phase 1 clinical trial for lead candidate PHI-101 (lasmotinib) in relapsed/refractory AML, received Orphan Drug Designation from the European Medicines Agency, and secured official registration of the international nonproprietary name lasmotinib with the World Health Organization as it prepares for global Phase 2 development and out-licensing. The company entered into a joint development agreement with Kolon Pharmaceutical for the co-development of PHI-701, secured Investigational New Drug approval from the Korean Ministry of Food and Drug Safety for PHI-501, and presented synergistic combination therapy data with menin inhibitors and immune checkpoint inhibitors at major scientific congresses. Additionally, the company streamlined its overseas operations by consolidating global clinical trial management through its Australian subsidiary, Pharos Therapeutics Pty Ltd, and expanded collaborative research initiatives with international institutions. Pharos iBio Co., Ltd. was founded in April 2016 and is headquartered in Seoul, South Korea, maintaining international clinical operations in Australia.